FDA-Subject by formulation interaction (Switchability) [Regulatives / Guidelines]

posted by jag009  – NJ, 2018-03-28 23:33 (1826 d 09:34 ago) – Posting: # 18607
Views: 2,600

❝ Now, as we are doing a fully replicate study as suggested by OGD recommendation on methyl­phenidate, can we use RSABE approach in case if we get ISCV-reference > 30% for any one of the PK parameter Cmax or partial AUCs, instead of using 90% CI calculation to prove the bio­equivalence?

Yes. Reason is that it is possible for one of those PK parameters to show ISCV > 30%.
As an added bonus, even if a BE guidance states that crossover studies are required but you have data to support that the drug of interest is HVD (ISCV>30%, provided that the high ISCV is not because your formulation is crap) then you can run the studies as replicates. I have done 2 projects in the past already.

P.S. You woke me up from my hibernation Helmut... :-)


Complete thread:

UA Flag
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
17 visitors (0 registered, 17 guests [including 7 identified bots]).
Forum time: 09:07 CEST (Europe/Vienna)

The function of genius is not to give new answers, but to pose
new questions which time and mediocrity can resolve.    H.R. Trevor-Roper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz